相关实验视频
Updated: Jun 26, 2025

09:38
Comprehensive Analysis of Drug Response using the FLICK Assay
Published on: June 6, 2025
59
对贝尔祖提凡的暴露-反应分析,以告知剂量考虑和标签
Dhananjay D Marathe1, Petra M Jauslin2, Huub Jan Kleijn2
1Merck & Co., Inc., Rahway, NJ, USA.
Journal of clinical pharmacology
|May 16, 2024
概括
贝尔祖提凡有效治疗与希佩尔-林道氏病相关的癌症. 暴露-反应分析证实了它的益处-风险概况,支持每日120毫克的剂量,而不需要针对特定患者群体进行调整.
科学领域:
- 药理学和瘤学 药理学和瘤学
- 临床试验分析
- 药物开发 药物开发
背景情况:
- 贝尔祖提凡是一种口服的缺氧诱导因子-2α抑制剂,已批准用于希佩尔-林道 (VHL) 疾病相关的细胞癌 (RCC) 和其他瘤.
- 临床研究评估了贝尔祖提凡在固体瘤,RCC和VHL-RCC中的安全性和有效性.
研究的目的:
- 进行暴露-反应 (E-R) 分析,以确定贝尔祖提凡的疗效和安全终点.
- 评估贝尔祖提凡暴露,疗效结果,安全事件和药理动力学生物标志物之间的关系.
主要方法:
- 人口的药理动力学建模以估计贝尔祖提凡的暴露.
- 用于ER评估的回归技术和时间到事件分析.
- 评估疗效 (反应率,PFS),安全性 (贫血,缺氧) 和生物标志物 (EPO,Hgb).
主要成果:
- 效率E-R分析显示,与非显著的积极趋势的关系一般是平坦的.
- 安全性 E-R 表示不与缺氧有任何关系,但与贫血有积极关系,受基线血红蛋白的影响.
- 观察到依赖于暴露的红素 (EPO) 和血红蛋白 (Hgb) 的减少.
结论:
- 贝尔祖提凡的益处与风险概况支持120毫克每日一次剂量用于与VHL疾病相关的瘤.
- 根据E-R分析,不建议对任何亚群进行先验剂量调整.
- 这些发现支持了贝尔祖提凡的标签和整体开发计划.
相关概念视频
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
125
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
125
Dose-Response Relationship: Potency and Efficacy
4.4K
The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it...
4.4K
Dose-Response Relationship: Overview
3.1K
Agonists can bind with and activate receptors, resulting in the formation of drug-receptor complexes. Once formed, these complexes catalyze many biochemical processes at the cellular level and subsequently induce a pharmacologic response. The degree of response is directly proportional to the fraction of activated receptors, which in turn, depends on the concentration of the drug at the receptor site as well as the sensitivity of the receptor. An increase in the administered dose contributes to...
3.1K
Pharmacovigilance
826
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
826
Dose-Response Relationship: Selectivity and Specificity
6.7K
Drugs exert their therapeutic effects by interacting with receptors, enzymes, or ion channels that are present throughout the human body. The strength and duration of the interaction between a drug and its target receptor are characterized by the selectivity and specificity of the drug. Selectivity refers to a drug's strong preference for its intended target over other targets. For instance, isoprenaline, a non-selective β-adrenergic agonist, interacts with both β1- and...
6.7K
Factors Affecting Drug Response: Overview
2.0K
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
2.0K

